Literature DB >> 27379922

Effects of short-term administration of tolvaptan after open heart surgery.

Katsuhiko Matsuyama1, Nobusato Koizumi2, Toshiya Nishibe2, Tomoaki Iwasaki2, Toru Iwahasi2, Kayo Toguchi2, Satoshi Takahashi2, Akinari Iwahori2, Keita Maruno2, Hitoshi Ogino2.   

Abstract

BACKGROUND: Postoperative fluid overload following cardiac surgery is associated with increased morbidity and mortality. Unlike loop diuretics, tolvaptan (TLV) promotes aquaretic effect. Relatively little has been documented regarding the efficacy of TLV after cardiac surgery. The aim of the study was to investigate the effectiveness and safety of tolvaptan for the management of immediately postoperative fluid retention following cardiac surgery.
METHODS: Between January to May 2014, patients undergoing cardiac surgery were randomly assigned to control or TLV group immediately after cardiac surgery. In control group, patients received 20mg of furosemide and 25mg of spironolactone as conventional diuretics. In the TLV group, 7.5mg of TLV was administered in combination with conventional diuretics.
RESULTS: TLV use was associated with increased urine output from postoperative day 1 to 3.Body weight reduction in the TLV group was significantly greater than the control group from postoperative day 2 to 4, and serum creatinine levels decreased to below preoperative values in the TLV group.
CONCLUSIONS: The combination of tolvaptan with conventional diuretics increases urine output without renal dysfunction and can be effective for postoperative fluid management and appropriate body weight reduction.
Copyright © 2016. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Diuretics; Heart failure; Surgery; Tolvaptan

Mesh:

Substances:

Year:  2016        PMID: 27379922     DOI: 10.1016/j.ijcard.2016.06.156

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Perioperative urinary excretion of aquaporin-2 dependent upon vasopressin in cardiac surgery.

Authors:  Masahiro Fujii; Ryosuke Amitani; Ryuzo Bessho
Journal:  Heart Vessels       Date:  2019-11-07       Impact factor: 2.037

2.  Safety and effectiveness of tolvaptan for fluid management after pediatric cardiovascular surgery.

Authors:  Yuzo Katayama; Tsukasa Ozawa; Noritsugu Shiono; Hiroshi Masuhara; Takeshiro Fujii; Yoshinori Watanabe
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-06-24

3.  First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery.

Authors:  Anne Kerling; Okan Toka; André Rüffer; Hanna Müller; Sheeraz Habash; Christel Weiss; Sven Dittrich; Julia Moosmann
Journal:  BMC Pediatr       Date:  2019-02-12       Impact factor: 2.125

4.  The Efficacy and Renal Protective Effect of Tolvaptan in Chronic Kidney Disease Patients after Open-Heart Surgery.

Authors:  Yasuhiro Futamura; Hirotaka Watanuki; Masaho Okada; Kayo Sugiyama; Katsuhiko Matsuyama
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-05-28       Impact factor: 1.520

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.